Astera Labs (NASDAQ:ALAB) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Key Points

• JPMorgan raised its price target on Astera Labs to $280 (from $205) with an "overweight" rating, implying about a 31% upside, while the consensus remains a "Moderate Buy" with a $227.90 average target.
• Astera Labs reported a strong Q1 beat (EPS $0.61 vs. $0.54 est.; revenue $308.4M, up ~93% YoY), issued upbeat Q2 guidance (EPS 0.68–0.70), and said its new 320‑lane Scorpio X series is shipping to hyperscalers—driving AI connectivity momentum.
• Investors should note high valuation and insider activity: the stock trades at a P/E of ~175 and insiders sold about 1,064,888 shares (~$150.8M) over the past three months, adding caution despite the operational strength.

Astera Labs (NASDAQ:ALAB - Get Free Report) had its price target boosted by equities research analysts at JPMorgan Chase & Co. from $205.00 to $280.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective would indicate a potential upside of 31.05% from the stock's previous close.

A number of other research firms have also weighed in on ALAB. Morgan Stanley raised their price target on shares of Astera Labs from $210.00 to $240.00 and gave the company an "overweight" rating in a research report on Wednesday. Rothschild & Co Redburn began coverage on shares of Astera Labs in a research report on Friday, May 1st. They set a "neutral" rating and a $153.00 price target on the stock. Jefferies Financial Group restated a "buy" rating and set a $270.00 price objective on shares of Astera Labs in a report on Wednesday. Barclays set a $165.00 price objective on shares of Astera Labs in a report on Thursday, January 15th. Finally, Weiss Ratings downgraded shares of Astera Labs from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, February 23rd. Fifteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $227.90.

Astera Labs Trading Down 0.9%

Shares of ALAB traded down $2.04 during trading hours on Wednesday, reaching $213.65. 8,527,278 shares of the stock traded hands, compared to its average volume of 5,381,641. The stock has a fifty day simple moving average of $140.72 and a 200 day simple moving average of $153.38. Astera Labs has a 52 week low of $63.40 and a 52 week high of $262.90. The company has a market cap of $36.59 billion, a price-to-earnings ratio of 175.13, a PEG ratio of 3.96 and a beta of 3.35.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The company had revenue of $308.36 million for the quarter, compared to analyst estimates of $292.19 million. During the same period last year, the firm earned $0.33 earnings per share. The firm's revenue was up 93.5% on a year-over-year basis. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. Analysts predict that Astera Labs will post 1.48 earnings per share for the current fiscal year.

Insider Transactions at Astera Labs

In other news, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $107.77, for a total value of $1,077,700.00. Following the completion of the transaction, the general counsel owned 118,084 shares in the company, valued at $12,725,912.68. This trade represents a 7.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Truett Tate sold 12,001 shares of Astera Labs stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total transaction of $1,485,843.81. Following the completion of the transaction, the chief financial officer owned 192,083 shares of the company's stock, valued at $23,781,796.23. The trade was a 5.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 1,064,888 shares of company stock valued at $150,764,723. 12.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Astera Labs

A number of large investors have recently modified their holdings of ALAB. Vanguard Group Inc. boosted its position in shares of Astera Labs by 14.1% in the third quarter. Vanguard Group Inc. now owns 13,743,141 shares of the company's stock valued at $2,690,907,000 after acquiring an additional 1,693,918 shares during the period. Atreides Management LP boosted its position in shares of Astera Labs by 2,496.6% in the fourth quarter. Atreides Management LP now owns 1,611,194 shares of the company's stock valued at $268,038,000 after acquiring an additional 1,549,144 shares during the period. Amundi boosted its position in shares of Astera Labs by 1,298.6% in the third quarter. Amundi now owns 1,421,263 shares of the company's stock valued at $278,283,000 after acquiring an additional 1,319,643 shares during the period. Rafferty Asset Management LLC bought a new position in shares of Astera Labs in the third quarter valued at approximately $209,599,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Astera Labs by 577.3% in the third quarter. BNP Paribas Financial Markets now owns 1,127,340 shares of the company's stock valued at $220,733,000 after acquiring an additional 960,899 shares during the period. 60.47% of the stock is currently owned by institutional investors.

Key Astera Labs News

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Q1 results materially beat expectations — EPS $0.61 vs. $0.54 est and revenue $308.4M (up ~93% YoY). Management raised Q2 revenue and EPS guidance well above consensus, signaling continued strength from PCIe‑6 and AI connectivity demand. Astera Labs Q1 Earnings Beat Estimates
• Positive Sentiment: Executive commentary and the earnings call highlighted explosive AI spending and that the new Scorpio X‑Series (320‑lane) switches are shipping to hyperscalers — a product cadence that could expand TAM and drive higher‑margin sales. Scorpio X‑Series Shipping
• Positive Sentiment: Margins and profitability surprised to the upside (gross margin expansion reported), and research notes highlight that ALAB is becoming a critical supplier for hyperscalers — supportive for medium‑term earnings power. Seeking Alpha: Superb Q1
• Neutral Sentiment: Analysts raised price targets — Stifel and Needham increased PTs to $260 with buy ratings, while Susquehanna raised its PT to $230 but kept a neutral rating; these moves validate the earnings beat but show varied conviction on valuation. Analyst Price‑Target Moves
• Neutral Sentiment: Major financial outlets summarized the call and market momentum — useful for sentiment but not new fundamental info. Earnings Call Highlights
• Negative Sentiment: Valuation concerns surfaced after the rally — some analysts and writeups are questioning whether the current share price fully reflects future growth, prompting profit‑taking and caution among some investors. Valuation Assessment

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.